Trial Allocation Specialist
- Research & Development
- Denmark - Søborg
Global Trial Allocation (GTA) is responsible for the patient allocation in all Novo Nordisk clinical trials. We work in a global and complex environment interacting with many stakeholders across the CMR organisation and HQ development projects. Novo Nordisk will in the coming years have an increasingly high activity level within clinical trials and product approvals. Hence transparency around the country allocations supported by in depth analysis, is key for a successful trial execution.
About the department
GTA is anchored in Strategic Development within Global Development, with the purpose of allocating patients into clinical trials and facilitating patient recruitment targets on CMR regional level. The department consists of four dedicated employees each with responsibilities towards the CMR organisation and key projects.
The job
You will be responsible for the global patient allocation into a number of our clinical trials. Patient allocation is based on a combined quantitative and qualitative approach, where clinical trial characteristics together with different and varied datasets are considered. Your overall task will be to translate this information, and combine it with cross-portfolio strategic considerations and insights into the CMR organisation, reaching meaningful and operational trial allocations. An understanding and/or knowledge of clinical development will be an advantage.The day to day activities of the department will bring you in close contact with the Global Development projects, and the CMR organisation. The GTA function has become a natural centre of excellence within short term patient forecasting, analysis, and strategic evaluations and we interact with many stakeholders globally and cross-functionally. You will report to the Director of GTA and as part of Strategic Development, Global Development, you will work closely with colleagues within this area.
Qualifications
You have a relevant University degree and analytical background. You could have a Bachelor or M.Sc. in natural science (eg. medicine, pharmacy, biology) with strong analytical skills. You may also have experience from clinical trial execution, preferably within the haemophilia area. You must be analytical, quality conscious, and have a track record within conduct of complex, cross-functional projects. As you will be working closely with colleagues across the organisation, it is very important that you have strong communication and stakeholder management skills. You are good at ‘talking with data and insights’. You have pharmaceutical industry experience, preferably within Novo Nordisk Clinical Development, and proven experience working within e.g. clinical operations. You are fluent in English, written and speech.
Contact
For further information, please contact Henrik Troelsen at +45 3079 4507.
Deadline
20 September 2013.
- Research & Development
- Denmark - Søborg
Global Trial Allocation (GTA) is responsible for the patient allocation in all Novo Nordisk clinical trials. We work in a global and complex environment interacting with many stakeholders across the CMR organisation and HQ development projects. Novo Nordisk will in the coming years have an increasingly high activity level within clinical trials and product approvals. Hence transparency around the country allocations supported by in depth analysis, is key for a successful trial execution.
About the department
GTA is anchored in Strategic Development within Global Development, with the purpose of allocating patients into clinical trials and facilitating patient recruitment targets on CMR regional level. The department consists of four dedicated employees each with responsibilities towards the CMR organisation and key projects.
The job
You will be responsible for the global patient allocation into a number of our clinical trials. Patient allocation is based on a combined quantitative and qualitative approach, where clinical trial characteristics together with different and varied datasets are considered. Your overall task will be to translate this information, and combine it with cross-portfolio strategic considerations and insights into the CMR organisation, reaching meaningful and operational trial allocations. An understanding and/or knowledge of clinical development will be an advantage.The day to day activities of the department will bring you in close contact with the Global Development projects, and the CMR organisation. The GTA function has become a natural centre of excellence within short term patient forecasting, analysis, and strategic evaluations and we interact with many stakeholders globally and cross-functionally. You will report to the Director of GTA and as part of Strategic Development, Global Development, you will work closely with colleagues within this area.
Qualifications
You have a relevant University degree and analytical background. You could have a Bachelor or M.Sc. in natural science (eg. medicine, pharmacy, biology) with strong analytical skills. You may also have experience from clinical trial execution, preferably within the haemophilia area. You must be analytical, quality conscious, and have a track record within conduct of complex, cross-functional projects. As you will be working closely with colleagues across the organisation, it is very important that you have strong communication and stakeholder management skills. You are good at ‘talking with data and insights’. You have pharmaceutical industry experience, preferably within Novo Nordisk Clinical Development, and proven experience working within e.g. clinical operations. You are fluent in English, written and speech.
Contact
For further information, please contact Henrik Troelsen at +45 3079 4507.
Deadline
20 September 2013.